Aegerion Pharmaceuticals, Inc. (AEGR), MannKind Corporation (MNKD): 3 Biotech Companies You Should Have Bought This Year

Page 2 of 2

The bigger risk is whether doctors will prescribe Afrezza and whether MannKind Corporation (NASDAQ:MNKD) can find a big pharma partner to help the biotech company change the paradigm of diabetes treatment. An uphill battle for sure.

Best buy?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and MannKind Corporation (NASDAQ:MNKD) looked like much better deals before their run-ups this year. I don’t see how their respective news — or lack thereof — makes the biotech companies worth nearly triple what they were valued at the beginning of the year.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is arguably worth more since it’s less risky and should be profitable sooner, but an FDA approval is still two years away, so there doesn’t seem to be any rush to jump into the biotech company anytime soon.

The article 3 Biotech Companies You Should Have Bought This Year originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned, and neither does The Motley Fool.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2